Valuation Gilead Sciences, Inc. Berne S.E.

Stocks

End-of-day quote Berne S.E. Other stock markets 10/02/2026			5-day change	1st Jan Change
115.86 ^CHF	+69.18%		+57.76%	+69.18%

07-30	Merck, Wellcome partner with global health group to make Ebola vaccine for clinical trials	RE
07-28	Atea Pharmaceuticals Says Combination Drug Meets Endpoints in Phase 3 Hepatitis C Trial	MT

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	91,081	107,677	100,942	115,118	152,281	161,665	-	-
Change	-	18.22%	-6.25%	14.04%	32.28%	6.16%	-	-
Enterprise Value (EV) ¹	118,530	126,522	118,665	131,838	169,585	171,262	161,665	151,709
Change	-	6.74%	-6.21%	11.1%	28.63%	0.99%	-5.6%	-6.16%
P/E	14.7x	23.6x	18x	243x	18.1x	-46.9x	16.5x	15.1x
PBR	4.32x	5.05x	4.48x	5.98x	6.73x	8.23x	6.43x	5.18x
PEG	-	-0.9x	0.8x	-2.7x	0x	0x	-0x	1.65x
Capitalization / Revenue	3.34x	3.95x	3.72x	4x	5.17x	5.31x	5.01x	4.74x
EV / Revenue	4.34x	4.64x	4.38x	4.59x	5.76x	5.63x	5.01x	4.45x
EV / EBITDA	8.12x	8.86x	9.01x	11.7x	10.6x	31.1x	9x	8.44x
EV / EBIT	9.45x	10.4x	11.3x	15.5x	12.9x	61.8x	10.4x	9.06x
EV / FCF	11x	15.2x	16x	12.8x	17.9x	212x	12.2x	10.8x
FCF Yield	9.12%	6.59%	6.25%	7.82%	5.58%	0.47%	8.2%	9.27%
Dividend per Share ²	2.84	2.92	3	3.08	3.16	3.296	3.409	3.102
Rate of return	3.91%	3.4%	3.7%	3.33%	2.57%	2.53%	2.62%	2.38%
EPS ²	4.93	3.64	4.5	0.38	6.78	-2.775	7.887	8.608
Distribution rate	57.6%	80.2%	66.7%	811%	46.6%	-119%	43.2%	36%
Net sales ¹	27,305	27,281	27,116	28,754	29,443	30,425	32,297	34,107
EBITDA ¹	14,598	14,283	13,177	11,287	15,953	5,510	17,953	17,972
EBIT ¹	12,548	12,180	10,484	8,520	13,193	2,771	15,584	16,737
Net income ¹	6,225	4,592	5,665	480	8,510	-3,391	9,779	10,495
Net Debt ¹	27,449	18,845	17,723	16,720	17,304	9,597	-	-9,955
Reference price ²	72.61	85.85	81.01	92.37	122.74	130.21	130.21	130.21
Nbr of stocks (in thousands)	1,254,384	1,254,244	1,246,042	1,246,266	1,240,680	1,241,570	-	-
Announcement Date	01/02/22	02/02/23	06/02/24	11/02/25	10/02/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (N)	EV / Sales (N)	EV / EBITDA (N)	Dividend Yield (N)	Capi.($)
ELI LILLY AND COMPANY	35.03x	12.19x	25.61x	0.59%	1,024B
JOHNSON & JOHNSON	27.48x	6.29x	17.54x	2.1%	618B
ABBVIE INC.	32.57x	7.42x	15.35x	2.76%	443B
ROCHE HOLDING AG	19.7x	4.68x	11.59x	2.83%	349B
ASTRAZENECA PLC	21.76x	4.48x	12.7x	1.96%	264B
NOVO NORDISK A/S	13.48x	5.05x	10.4x	3.71%	209B
AMGEN INC.	25.29x	6.61x	11.66x	2.62%	208B
PFIZER INC.	12.69x	3.11x	7.86x	6.88%	143B
BRISTOL-MYERS SQUIBB COMPANY	11.77x	3.27x	8.54x	3.87%	133B
Average	22.20x	5.90x	13.47x	3.03%	376.74B
Weighted average by Cap.	26.95x	7.60x	17.14x	2.19%